PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx Addressing Patients with Recurrent Pericarditis
Cardiol Therapeutics President and CEO, David Elsley PRISM MarketView announces the release of an informative interview with Cardiol Therapeutics President and CEO,